BioSpace News Archive

BioForest

10 Life Science Innovators Under 40 to Watch

There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators.

July 9, 2019
·
4 min read
·
Mark Terry
Despite IPO Rumors, BioNTech Closes Upsized Series B Worth $325 Million

This makes it one of the biggest single private funding rounds for a biotechnology company in European history.

July 9, 2019
·
3 min read
·
Mark Terry
Policy

Judge Strikes Down Trump’s Rule Mandating Drug Price Disclosure in TV Ads

The judge ruled that the U.S. Department of Health and Human Services did not have the authority to compel companies to disclose the list prices without Congressional approval.

July 9, 2019
·
3 min read
·
Alex Keown
BioCapital

PhRMA-backed Study Shows Hospitals Significantly Hike Drug Prices

The study data shows that the amount hospitals receive after negotiations with commercial payers is, on average, almost twice what they paid to acquire the medicine.

July 9, 2019
·
2 min read
·
Alex Keown
Immunotherapy could work against bowel cancers resistant to important targeted treatment

Patients with bowel cancer who have stopped responding to a widely used targeted drug could benefit from immunotherapy, a major new study reveals.

July 9, 2019
·
7 min read
Biotech Bay

Revolution Medicines Snags $100 Million to Target RAS Pathway

Bay Area-based Revolution Medicines Inc. secured $100 million in Series C financing that will be used to support the development of the company’s pipeline of drugs that target the RAS pathway, including its lead clinical candidate.

July 9, 2019
·
2 min read
·
Alex Keown
Business

J&J’s Janssen Doubles Down on Bioinformatics with Celsius Therapeutics Partnership

Under the terms of the agreement, Celsius will use its single-cell genomics and machine learning platform to attempt to identify predictive biomarkers from Janssen’s VEGA Phase IIa clinical trial.

July 9, 2019
·
2 min read
·
Mark Terry
Addex-Led Consortium Receives €4.85 Million Eurostars Grant to Develop Novel Allosteric Modulator to Treat Post-Traumatic Stress Disorder (PTSD)

Addex Therapeutics announced that it will lead a consortium for the development of small-molecule negative allosteric modulators targeting the metabotropic glutamate receptor 7 as a potential treatment to reduce fear memory in post-traumatic stress disorder.

July 9, 2019
·
4 min read
Drug Development

Karolinska Development’s portfolio company Dilafor initiates Phase 2b clinical trial with tafoxiparin in women planned for labor induction

Karolinska Development’s portfolio company Dilafor AB, a drug development company focusing on the development of tafoxiparin for obstetric indications, has enrolled the first subject in its Phase 2b study with tafoxiparin in pregnant women planned for labor induction.

July 9, 2019
·
2 min read
Immunotherapy specialist benefits from Quantum bioprocessing pump

An immunotherapy specialist is leveraging the advantages of investing in a new Quantum bioprocessing pump from Watson-Marlow Fluid Technology Group (WMFTG).

July 9, 2019
·
3 min read